Buontempo, Francesca <br/><br/>
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.  [electronic resource] 

 -  Oncotarget  Jan 2016 
 - 1323-40 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.6361  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Bortezomib--pharmacology<br/>Casein Kinase II--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Drug Synergism<br/>Endoplasmic Reticulum Chaperone BiP<br/>Endoplasmic Reticulum Stress--drug effects<br/>Heat-Shock Proteins--metabolism<br/>Humans<br/>Jurkat Cells<br/>Microscopy, Fluorescence<br/>Naphthyridines--pharmacology<br/>Neoplastic Stem Cells--drug effects<br/>Phenazines<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--blood<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--blood<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--blood<br/>Transcription Factor RelA--metabolism<br/>Unfolded Protein Response--drug effects